Patents Represented by Attorney Vance Intellectual Property, PC

Find this attorney in the Justia Lawyer Directory

  • Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 8088798
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: February 6, 2010
    Date of Patent: January 3, 2012
    Assignee: Jensen Discovery, Inc.
    Inventors: John Francis McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8088809
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: January 3, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Functionalized biodegradable triclosan monomers and oligomers for controlled release
    Patent number: 8053591
    Abstract: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: November 8, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S. Bezwada
  • Hydrolysable linkers and cross-linkers for absorbable polymers
    Patent number: 8048980
    Abstract: The present invention relates to the discovery of new class of linear and multiarmed hydrolysable linkers and cross linkers for use in the synthesis of biodegradable polymers as, polyesters, polyurethanes, polyamides, polyureas and degradable epoxy amine resin. The linear and multiarmed hydrolysable linkers of the present invention include symmetrical and/or unsymmetrical ether carboxylic acids, amines, amide diols, amine polyols and isocyanates.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: November 1, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S. Bezwada
  • Deuterium-enriched topotecan
    Patent number: 8026249
    Abstract: The present application describes deuterium-enriched topotecan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: September 27, 2011
    Assignee: Deutena Pharmaceuticals, Inc.
    Inventor: Anthony W. Czarnik
  • Control release of biologically active compounds from multi-armed oligomers
    Patent number: 8026285
    Abstract: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: September 27, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S. Bezwada
  • Difunctionalized aromatic compounds and polymers therefrom
    Patent number: 8007526
    Abstract: The present invention relates to compounds of formula I, which are difunctionalized aromatic compounds, and polymers formed from the same. Polymers formed from the di-functionalized aromatics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: August 30, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Deuterium-enriched SDX-101
    Patent number: 7956080
    Abstract: The present application describes deuterium-enriched SDX-101, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: June 7, 2011
    Assignee: Protra, LLC
    Inventor: Anthony W. Czarnik
  • MAO-B inhibitors useful for treating obesity
    Patent number: 7956220
    Abstract: The invention provides novel compounds of formulae I and II: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: June 7, 2011
    Assignee: Jenrin Discovery
    Inventors: John Francis McElroy, Robert J. Chorvat, Rajagopalan Parthasarathi
  • Functionalized diphenolics and absorbable polymers therefrom
    Patent number: 7935843
    Abstract: The present invention relates to dephenolic compounds, an example of which is shown below, which are functionalized, and polymers formed from the same. Polymers formed from the functionalized diphenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: May 3, 2011
    Assignee: Bezwada Biomedical, LLC
    Inventor: Rao S Bezwada
  • Parenteral solutions containing metolazone
    Patent number: 7923447
    Abstract: Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: April 12, 2011
    Assignee: Academic Pharmaceuticals Incorporated
    Inventors: John C. Somberg, Vasant V. Ranade
  • Deuterium-enriched oseltamivir
    Patent number: 7915309
    Abstract: The present application describes deuterium-enriched oseltamivir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: March 29, 2011
    Assignee: Protia, LLC
    Inventor: Anthony W. Czarnik
  • Deuterium-enriched nelarabine
    Patent number: 7846912
    Abstract: The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: December 7, 2010
    Assignee: Protia, LLC
    Inventor: Anthony W. Czarnik
  • Deuterium-enriched capecitabine
    Patent number: 7842675
    Abstract: The present application describes deuterium-enriched capecitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: November 30, 2010
    Assignee: Protia, LLC
    Inventor: Anthony W. Czarnik
  • Deuterium-enriched risperidone
    Patent number: 7776866
    Abstract: The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: August 17, 2010
    Assignee: Protia, LLC
    Inventor: Anthony W Czarnik
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 7759335
    Abstract: The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: July 20, 2010
    Assignee: Jenrm Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Deuterium-enriched atorvastatin
    Patent number: 7745480
    Abstract: The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: June 29, 2010
    Assignee: Protia, LLC
    Inventor: Anthony W. Czarnik
  • Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 7687481
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: March 30, 2010
    Assignee: Jenrin Discovery, Inc.
    Inventors: John Francis McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 7666889
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: February 23, 2010
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 7655685
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: February 2, 2010
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat